Olaparib

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Olaparib
    1. Pharmacist Assessment Report
    2. Olaparib: Known uses and market status in India
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. India Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Disclaimer

Pharmacist Assessment Report

Olaparib: Known uses and market status in India

Summary

All candidates produced by the model for Olaparib are already known uses, so there is currently no new predicted indication. The one traceable candidate falls in the same disease category as an approved indication. It is not a new finding.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 1
Evidence level Not applicable
India Market Status Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products 2 (valid: 2)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
female breast carcinoma breast cancer

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence Product Dosage form Status
123582 Lynparza 100mg Tablet strip of 8 tablets Valid
121540 Lynparza 150mg Tablet strip of 8 tablets Valid

Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy (PARP inhibitor)
Myelosuppression Risk Please refer to the package insert warnings and precautions
Emetogenicity Classification Please refer to the package insert warnings and precautions
Monitoring Items Complete blood count, liver and renal function (general oncology practice; confirm against the package insert)
Handling Protection Please refer to the package insert warnings and precautions

Safety Considerations

  • Drug Interactions: 444 interactions were recorded. Examples of those rated Major: aprepitant, dexamethasone and clarithromycin. Examples rated Moderate: metformin, bupropion, cimetidine, miconazole, clotrimazole, glyburide, ondansetron, repaglinide, rosuvastatin and simvastatin. Several of the Major and Moderate interactions involve drugs commonly used in oncology supportive care (antiemetics, corticosteroids), so concomitant medications should be reviewed.

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.